Study to Assess Safety, Tolerability and Activity of DSB2455 in Participants With Advanced Malignancies

Summary

Open label, multi-centre, Phase Ia/b adaptive design study with an initial 2-stage Dose Escalation Phase followed by a Dose Expansion Phase.

Timeline

Start

2024-11-21

Primary completion

2028-08

Completion

2028-12

Drugs

Indications